Biosimilars

Photo
08.03.2024 • News

Sandoz Acquires Ophthalmology Franchise from Coherus

In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.

Photo
30.01.2024 • News

Gedeon Richter Becomes Strategic Investor of Formycon

Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.

Photo
13.09.2023 • TopicsPharma

The Success Story of Biosimilars

With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.

46 more articles

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.